clazakizumab in antibody mediated rejection

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
clazakizumab in antibody mediated rejection	1.29	0.3	5248	34	43
clazakizumab	1.26	0.8	1323	68	12
in	1.14	0.3	684	67	2
antibody	1.78	0.5	7888	35	8
mediated	1	0.8	7340	61	8
rejection	0.35	0.1	1918	28	9

Keyword	CPC	PCC	Volume	Score
eculizumab antibody mediated rejection	1.87	0.1	6580	49
daratumumab antibody mediated rejection	1.22	0.7	4799	19
carfilzomib for antibody mediated rejection	0.65	0.3	4065	19
mepolizumab reslizumab and benralizumab	1.41	0.4	1616	26
daratumumab and antibody screening	0.01	0.3	2445	64
daratumumab and blood antibodies	0.86	0.9	1573	70
daratumumab and radiation therapy	0.72	0.3	7655	96
does daratumumab cause immunosuppression	1.71	0.8	5157	78
anti-daratumumab	0.46	0.2	2877	68
daratumumab and irradiated blood	0.98	0.8	4572	93
daratumumab mode of action	0.38	0.2	934	29
daratumumab mechanism of action	0.92	0.7	7551	63
daratumumab up to date	1.37	0.2	1493	22
daratumumab effects on blood	0.38	0.9	3874	3
daratumumab modality of action	1.75	0.6	5832	14
daratumumab infusion reaction treatment	1.64	0.1	2345	82
daratumumab is it immunotherapy	1.16	0.9	3835	60
daratumumab type and screen	0.34	0.7	8055	14
daratumumab chemo or immunotherapy	1.64	0.7	8715	9
is daratumumab a checkpoint inhibitor	0.24	0.5	445	91
daratumumab and blood transfusion	0.27	0.6	5838	19
daratumumab for cancer patients	1.96	0.7	6610	17
daratumumab in multiple myeloma	0.62	0.2	8898	25
daratumumab for cancer treatment	1.69	1	7911	26
fda approval for daratumumab	1.03	0.5	957	35